Hospitalisation for heart failure and mortality associated with dipeptidyl peptidase 4 (DPP-4) inhibitor use in an unselected population of subjects with type 2 diabetes: a nested case-control study

Giorda, Carlo B.; Picariello, Roberta; Tartaglino, Barbara; Marafetti, Lisa; Di Noi, Fabiana; Alessiato, Annalisa; Costa, Giuseppe; Gnavi, Roberto
June 2015
BMJ Open;Jun2015, Vol. 5 Issue 6, p1
Academic Journal
No abstract available.


Related Articles

  • Dipeptidyl peptidase-4 inhibitors and risk of heart failure in type 2 diabetes.  // BMJ: British Medical Journal;2/20/2016, Vol. 352 Issue 8045, p270 

    The article examines observational studies and randomized trials which investigated whether dipeptidyl peptidase-4 (DPP-4) inhibitors increases the risk of heart failure in type 2 diabetes patients. Topics covered include low quality evidence indicating that there is no increase in the risk of...

  • No Increased CV Events with DPP-4 Inhibitors. Buckley, Rita // MD Conference Express;Dec2011, p11 

    The article presents a study on the effects of dipeptidyl peptidase-4 (DPP-4) inhibitors on cardiovascular (CV) events in type 2 diabetes patients. It mentions that there are no increased CV events associated with DPP-4 inhibitors. It notes that DPP-4 inhibitors provides a possible protective...

  • Hospitalisation for HF assessed with various T2DM therapies.  // Reactions Weekly;2/6/2016, Vol. 1587 Issue 1, p9 

    An abstract of the article "Association Between Hospitalization for Heart Failure and Dipeptidyl Peptidase-4 Inhibitors in Patients With Type 2 Diabetes: An Observational Study" by A.Z. Fu and others is presented.

  • COMMENTARY. Bolen, Shari D. // BMJ: British Medical Journal;2/20/2016, Vol. 352 Issue 8045, pi801 

    The author discusses two studies which investigated whether incretin based drugs for treatment of type 2 diabetes increase the risk of heart failure and pancreatic cancer. One of the studies found no reported increase in pancreatic cancer risk in patients taking dipeptidyl peptidase-4 (DPP-4)...

  • Prolyl Peptidases Related to Dipeptidyl Peptidase IV: Potential of Specific Inhibitors in Drug Discovery. Van der Veken, Pieter; Haemers, Achiel; Augustyns, Koen // Current Topics in Medicinal Chemistry;Mar2007, Vol. 7 Issue 6, p621 

    Dipeptidyl peptidase IV (DPP IV) is a validated target for the treatment of type 2 diabetes, with several inhibitors currently in phase 3 clinical trials. This review will mainly focus on proline-specific dipeptidyl peptidases related to DPP IV: fibroblast activation protein (FAP), dipeptidyl...

  • Type 2 Diabetes Drug Shows Promise for Type 1. Stein, Jill // Renal & Urology News;Dec2010, Vol. 9 Issue 12, p28 

    The article reports on the approval of dipeptidyl peptidase (DPP)-4 inhibitor sitagliptin which is for the treatment of adult patients with type 2 diabetes.

  • Acute Pancreatitis in Patients with Type 2 Diabetes Mellitus Treated with Dipeptidyl Peptidase-4 Inhibitors: A Population-Based Nested Case-Control Study. Chou, Hsin-Chun; Chen, Wen-Wen; Hsiao, Fei-Yuan // Drug Safety;Jul2014, Vol. 37 Issue 7, p521 

    Background: Concern about an increasing risk of acute pancreatitis associated with incretin-based drugs, including dipeptidyl peptidase-4 (DPP-4) inhibitors and glucagon-like peptide-1 analogs, has emerged recently. Objective: This nested case-control study examined the association between the...

  • Cardiovascular Outcomes of Sitagliptin in Type 2 Diabetic Patients with Acute Myocardial Infarction, a Population-Based Cohort Study in Taiwan. Wang, Szu-Heng; Chen, Dong-Yi; Lin, Yu-Sheng; Mao, Chun-Tai; Tsai, Ming-Lung; Hsieh, Ming-Jer; Chou, Chung-Chuan; Wen, Ming-Shien; Wang, Chun-Chieh; Hsieh, I-Chang; Hung, Kuo-Chun; Chen, Tien-Hsing // PLoS ONE;Jun2015, Vol. 10 Issue 6, p1 

    Background: The cardiovascular safety and efficacy of sitagliptin, a dipeptidyl peptidase 4 (DPP-4) inhibitor, in type 2 diabetic patients after acute myocardial infarction (AMI) has so far remained uncertain. Methods: We analyzed data from the National Health Insurance Research Database...

  • Incretin-Based Drugs and the Risk of Congestive Heart Failure. Yu, Oriana Hoi Yun; Filion, Kristian B.; Azoulay, Laurent; Patenaude, Valerie; Majdan, Agnieszka; Suissa, Samy // Diabetes Care;Feb2015, Vol. 38 Issue 2, p277 

    OBJECTIVE To determine whether the use of incretin-based drugs, including GLP-1 analogs and dipeptidyl peptidase-4 inhibitors, is associated with an increased risk of congestive heart failure (CHF) among patients with type 2 diabetes. RESEARCH DESIGN AND METHODS The U.K. Clinical Practice...

  • INTEGRATED PHYSIOLOGY--INSULIN SECRETION IN VIVO.  // Diabetes;Jun2008 Supplement 1, Vol. 57, pA710 

    The article offers information on different studies about diabetes with topics on adiponectin and the first two types of diabetes, dipeptidyl peptidase 4 (DPP4) inhibitor, sulfonylurea-induced hypoglycemia, insulin secretion and insulin action in Chinese non-obese euglycemic first-degree...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics